LabCorp licenses Arcturus Bioscience's technology for cancer of unknown primary origin

By Jennifer Chiou

New York, Nov. 1 - Laboratory Corp. of America Holdings said it entered into an agreement with Arcturus Bioscience, Inc. to license its technology for cancer of unknown primary origin.

The 92-gene, PCR-based technology classifies 39 tumor types.

Terms of the multi-year agreement were not disclosed.

"Primary diagnosis is important in treating malignant diseases since predictions about tumor behavior and determination of appropriate therapy are based on the primary tumor site," said Myla Lai-Goldman, LabCorp executive vice president, chief scientific officer and medical director, in a news release.

"Even with metastasis, some neoplasms may still be responsive to therapy."

Burlington, N.C.-based LabCorp specializes in oncology testing.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.